ALPHA-TOCOPHEROL, BETA-CAROTENE LUNG CANCER PREVENTION STUDY

α-生育酚、β-胡萝卜素预防肺癌的研究 (ATBC研究)正在调查每日口服α-生育酚的疗效 (50毫克)和β-胡萝卜素(20毫克)，随机双盲2x2 旨在预防50-69岁肺癌的析因设计试验 年迈的男性烟民。该项目是基于实验和 具有潜在预防作用的流行病学研究 对这些特工来说。招募是在1985-88年间进行的，审判期间 干预在平均随访后按计划于1993年3月31日结束 六年多了。对潜在试验参与者的邮寄调查筛选 发送给芬兰南部的291,000名男性，76%的人做出了回应。我们 邀请愿意参与的吸烟者(43,000人)参加13项研究之一 诊所，超过29,000人被随机纳入研究。遵守 每天服用一粒胶囊的比例仍然很高(平均为97%)， 平均每年的辍学率不到6%。肺复位术 活性药物组的癌症发病率是主要的研究目标； 还将评估其他癌症发生的差异。 支持该试验的几项试点研究也已完成。 包括可行性研究，研究饮食问卷的验证， 并评估皮肤变黄和血清水平在贝塔- 胡萝卜素管理。 这项试验是与监督中心合作进行的 计划和癌症预防部门的生物测量学分部 并与芬兰国家公共卫生研究所合作。

The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study (ATBC Study) is investigating the efficacy of daily oral alpha-tocopherol (50 mg) and beta-carotene (20 mg) in a double-blind, randomized 2x2 factorial design trial aimed at preventing lung cancer among 50-69 year old male cigarette smokers. The project is based on experimental and epidemiological research which demonstrates a potential preventive role for these agents. Recruitment took place between 1985-88, and the trial intervention ended on schedule March 31, 1993 after an average followup of over 6 years. A postal survey screening for potential trial participant was sent to 291,000 men in southern Finland, and 76% responded. We invited the smokers willing to participate (43,000) to one of 13 study clinics, and over 29,000 were randomized into the study. Compliance to the one capsule daily regimen has remained very high (97% average), and the dropout rate averages less than 6% per year. Reduction of lung cancer incidence in the active agent groups is the primary study goal; differences in the occurrence of other cancers will also be evaluated. Several pilot studies in support of the trial have also been completed including a feasibility study, validation of study dietary questionnaires, and evaluation of skin yellowing and serum levels following beta- carotene administration. This trial is being conducted collaboratively with the Surveillance Program and the Biometry Branch of the Division of Cancer Prevention and Control and with the National Public Health Institute of Finland.